The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Researchers reviewed data from 14 hemophilia patients treated with Sevenfact to better understand its real-world safety and ...

for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

The Food and Drug Administration approved Pfizer’sPFE-0.17%decrease; red down pointing triangle Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia ...

During his bleeding episodes, his family used to take him to the nearby government hospital where his bleeding used to be managed by “giving him blood” and he was treated as a ‘suspected hemophilia ...

Hemlibra, a treatment for hemophilia A, knew it had to ditch the traditional approach and ... a unisex fragrance focusing on Astepro’s fast relief of allergy symptoms. With 1.83 billion earned ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment concizumab. Meanwhile, PTC Therapeutics' troubled ...

(Image Credits: Pixabay) The U.S. Food and Drug Administration (USFDA) approved Hympavzi (marstacimab-hncq) for patients suffering from Hemophilia A or B. According to a press statement ...

"Today's approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process," Ann Farrell ...